Biodesix Plunges 31.82% on Earnings Miss

On May 15, 2025, Biodesix's stock price plummeted by 31.82% in pre-market trading, marking a significant decline for the company.

Biodesix reported a quarterly loss of 8 cents per share, falling short of the analyst consensus estimate of 7 cents per share. This financial performance, coupled with revenue that missed expectations, has raised concerns among investors.

The company's revenue for the quarter was $17.96 million, which was below the consensus estimate of $20.24 million. Despite this shortfall, Biodesix's revenue for the first quarter of 2025 was $18.0 million, reflecting a 21% year-over-year increase. The company also achieved a gross margin of 79.4% and noted an 18% improvement in net loss compared to the same period last year.

Biodesix has updated its revenue guidance for 2025 to a range of $80-85 million, with expectations of achieving adjusted EBITDA positivity by the fourth quarter. The company has also highlighted a strategic reconfiguration of its sales team to enhance market reach, which is expected to bolster long-term growth.

Analysts have lowered their forecasts for Biodesix following the downbeat earnings report, citing disruption from a sales reconfiguration and a Q1 volume and revenue miss. The firm believes Biodesix is likely to sell off even further on these factors.